Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil
Renal medullary carcinoma (RMC) is rare, accounting for less than 1% of all renal neoplasms. Case reports suggest RMC is highly aggressive, poorly responsive to chemotherapy, often metastatic at diagnosis, affects young men with sickle cell trait, and median overall survival (mOS) is less than 12 mo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-08-01
|
| Series: | Rare Tumors |
| Subjects: | |
| Online Access: | http://www.pagepress.org/journals/index.php/rt/article/view/4751 |
| _version_ | 1818299419919908864 |
|---|---|
| author | Marina Cavalcanti Maroja Silvino Camila Motta Venchiarutti Moniz Gustavo Henrique Munhoz Piotto Sheila Siqueira Ariel Galapo Kann Carlos Dzik |
| author_facet | Marina Cavalcanti Maroja Silvino Camila Motta Venchiarutti Moniz Gustavo Henrique Munhoz Piotto Sheila Siqueira Ariel Galapo Kann Carlos Dzik |
| author_sort | Marina Cavalcanti Maroja Silvino |
| collection | DOAJ |
| description | Renal medullary carcinoma (RMC) is rare, accounting for less than 1% of all renal neoplasms. Case reports suggest RMC is highly aggressive, poorly responsive to chemotherapy, often metastatic at diagnosis, affects young men with sickle cell trait, and median overall survival (mOS) is less than 12 months. We report the epidemiological characteristics, treatments performed, response rate to each treatment and mOS of five patients with RMC. All patients had sickle cell trait, four were male, three had metastatic disease at diagnosis and mean age at diagnosis was 25 years. Non-metastatic patients were submitted to nephrectomy. Two patients had partial response to first line chemotherapy including cisplatin and gemcitabine. There was no response to sunitinib or second line chemo - therapy; mOS was 6 months. Due to its rarity, case series are the only evidence available to discuss the treatment for RMC. In our experience, only cisplatin and gemcitabine based regimen offered response. |
| first_indexed | 2024-12-13T04:50:56Z |
| format | Article |
| id | doaj.art-2e61cff4d68e4e3a9b4a8ba467c98dae |
| institution | Directory Open Access Journal |
| issn | 2036-3605 2036-3613 |
| language | English |
| last_indexed | 2024-12-13T04:50:56Z |
| publishDate | 2013-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Rare Tumors |
| spelling | doaj.art-2e61cff4d68e4e3a9b4a8ba467c98dae2022-12-21T23:59:00ZengSAGE PublishingRare Tumors2036-36052036-36132013-08-0153e44e4410.4081/rt.2013.e442581Renal medullary carcinoma response to chemotherapy: a referral center experience in BrazilMarina Cavalcanti Maroja Silvino0Camila Motta Venchiarutti Moniz1Gustavo Henrique Munhoz Piotto2Sheila Siqueira3Ariel Galapo Kann4Carlos Dzik5Instituto do Câncer de São Paulo, Faculdade de Medicina da Universidade de São PauloInstituto do Câncer de São Paulo, Faculdade de Medicina da Universidade de São PauloInstituto do Câncer de São Paulo, Faculdade de Medicina da Universidade de São PauloHospital das Clínicas, Faculdade de Medicina da Universidade de São PauloInstituto do Câncer de São Paulo, Faculdade de Medicina da Universidade de São PauloInstituto do Câncer de São Paulo, Faculdade de Medicina da Universidade de São PauloRenal medullary carcinoma (RMC) is rare, accounting for less than 1% of all renal neoplasms. Case reports suggest RMC is highly aggressive, poorly responsive to chemotherapy, often metastatic at diagnosis, affects young men with sickle cell trait, and median overall survival (mOS) is less than 12 months. We report the epidemiological characteristics, treatments performed, response rate to each treatment and mOS of five patients with RMC. All patients had sickle cell trait, four were male, three had metastatic disease at diagnosis and mean age at diagnosis was 25 years. Non-metastatic patients were submitted to nephrectomy. Two patients had partial response to first line chemotherapy including cisplatin and gemcitabine. There was no response to sunitinib or second line chemo - therapy; mOS was 6 months. Due to its rarity, case series are the only evidence available to discuss the treatment for RMC. In our experience, only cisplatin and gemcitabine based regimen offered response.http://www.pagepress.org/journals/index.php/rt/article/view/4751kidney neoplasms, renal medullary carcinoma, carcinoma, renal cell, sickle cell trait. |
| spellingShingle | Marina Cavalcanti Maroja Silvino Camila Motta Venchiarutti Moniz Gustavo Henrique Munhoz Piotto Sheila Siqueira Ariel Galapo Kann Carlos Dzik Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil Rare Tumors kidney neoplasms, renal medullary carcinoma, carcinoma, renal cell, sickle cell trait. |
| title | Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil |
| title_full | Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil |
| title_fullStr | Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil |
| title_full_unstemmed | Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil |
| title_short | Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil |
| title_sort | renal medullary carcinoma response to chemotherapy a referral center experience in brazil |
| topic | kidney neoplasms, renal medullary carcinoma, carcinoma, renal cell, sickle cell trait. |
| url | http://www.pagepress.org/journals/index.php/rt/article/view/4751 |
| work_keys_str_mv | AT marinacavalcantimarojasilvino renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil AT camilamottavenchiaruttimoniz renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil AT gustavohenriquemunhozpiotto renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil AT sheilasiqueira renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil AT arielgalapokann renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil AT carlosdzik renalmedullarycarcinomaresponsetochemotherapyareferralcenterexperienceinbrazil |